1. Leucht S et al. Lancet 2003 ; 361 : 1581-1589 2. Clark NG. Diabetes Care. 2004 ; 27 :596-601 3. From The Medical Letter. Treatment Guidelines 2004; 2 : 6-8 4. Carr V. Australian Prescriber 2004; 27:149-151 5. Gill SS et al.BMJ 2005 Feb 26; 330:445 6. Liperoti R et al.Arch Intern Med. 2005 Mar 28; 165:696-701 7. Ballard C et al. BMJ 2005 Apr 16; 330: 874 8. http://www.fda.gov/cder/drug/infopage/antipsychotics/default.htm 9. Focus. Bollettino di Farmacovigilanza n. 37, febbraio-maggio 2004. In: http://www.sfm.univr.it/ 10. E. Wooltorton. Health and Drug Alerts. CMAJ 2002 Nov 26: 167:1269 11.E. Wooltorton. Health and Drug Alerts. CMAJ 2004 Apr 27, 170:1395 12. Proietto J et al. Diabetes and antipsychotic drugs. Austr Prescriber 2004 n. 5; 27:118-119 13. Singh S et al. Health and Drug Alerts. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 2005 Aug 2; 173:252. 14. Lieberman JA et al. For the Clinical Antipsychotic Trials of Intervention of Effectivenes (CATIE) Investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med 2005 Sept 22; 353:1209-1223. 15. Wang PS et al. Risk of Death in Elderly Users of Conventional vs Atypical Antipsychotic Medications. N Engl J Med 2005 Dec 1; 353: 2335-2341 16. Jones PB et al. Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) . Arch Gen Psychiatry. 2006 Oct;63:1079-1087 17. Schneeweiss S et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007 Feb 27; 176:627-32 18. Gill SS et al. Antipsychotic Drug Use and Mortality in Older Adults with Dementia. Ann Intern Med 2007 Jun 5; 146.775-786
|
|
